Clinical trials: Clinical Trial, Phase I
Dyslipidemia
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.
- Trial name
- CKD-519 FIH (NCT02156544)
- Testing
- CKD-519
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Solid Malignancies
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
- Trial name
- NCT00162136
- Testing
- Ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- R-Pharm
FDC, Diabetes Mellitus, Type 2
To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination
To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.
- Trial name
- NCT05737771
- Testing
- DWC202213, DWJ1563, DWP16001
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Advanced Solid Tumors
Study of CM518D1 in Patients With Advanced Solid Tumors
This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.
- Trial name
- NCT07019779
- Testing
- CM518D1
- Where
- China
- Volunteers
- 434 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard…
- Trial name
- NCT07222969
- Testing
- VIB305 for Injection
- Where
- 2 sites in Australia, China
- Volunteers
- 146 people
- Sponsor
- Vibrant Sciences Limited
Rheumatoid Arthritis
A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.
This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.
- Trial name
- NCT05874622
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Hormone Refractory Prostate Cancer
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given…
- Trial name
- NCT00477529
- Testing
- ABI-008
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Celgene
Advanced Solid Malignancies
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR115 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and…
- Trial name
- NCT06388902
- Testing
- BR115 for injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Advanced/Metastatic Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid…
- Trial name
- NCT07480681
- Testing
- HLX97, Fulvestrant
- Volunteers
- 138 people
- Sponsor
- Shanghai Henlius Biotech
Hypertension
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers
To evaluate the safety and pharmacokinetic characteristics of AJU-C52L in healthy adults
- Trial name
- NCT05077475
- Testing
- C52R1H Tab. and C52R2 Tab., AJU-C52L
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Healthy Volunteers
Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers
The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.
- Trial name
- NCT05346601
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Widespread Small Cell Lung Cancer
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide…
- Trial name
- NCT07009457
- Testing
- SHR-1316 (sc) Injection, SHR-1316 Injection, Carboplatin Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Leptomeningeal Metastasis, Solid Tumor, Adult
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
- Trial name
- NCT04315246
- Testing
- radiolabeled DPTA-omburtamab
- Where
- 8 sites in United States, United Kingdom
- Sponsor
- Y-mAbs Therapeutics
Solid Tumor
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With…
- Trial name
- NCT06215846
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Chronic Hepatitis B
GLS4/RTV and TAF Drug-drug Interaction
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.
- Trial name
- NCT04551261
- Testing
- GLS4, RTV, TAF
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Carcinoma, Renal Cell, Carcinoma Colon
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies.
- Trial name
- RENACOL (NCT05104905)
- Testing
- bexmarilimab
- Where
- Finland
- Sponsor
- Faron Pharmaceuticals Ltd
Breast Neoplasms
Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
- Trial name
- NCT02254031
- Testing
- bivatuzumab mertansine
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
- Trial name
- NCT01159028
- Testing
- BP1001, BP1001 in combination with LDAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bio-Path Holdings, Inc.
Carcinoma, Non-small Cell Lung Cancer
Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).
- Trial name
- NCT00599755
- Testing
- Comparator: CT or MRI and FDG-PET, Gemcitabine and Cisplatin or Gemcitabine and Carboplatin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.